vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and XPLR Infrastructure, LP (XIFR). Click either name above to swap in a different company.
XPLR Infrastructure, LP is the larger business by last-quarter revenue ($249.0M vs $247.1M, roughly 1.0× ANI PHARMACEUTICALS INC). XPLR Infrastructure, LP runs the higher net margin — 11.2% vs 11.1%, a 0.1% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs -15.3%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-88.0M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -1.6%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
XPLR Infrastructure is a publicly traded subsidiary of NextEra Energy, is a Juno Beach, Florida-based renewable energy company.
ANIP vs XIFR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $249.0M |
| Net Profit | $27.5M | $28.0M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | -19.3% |
| Net Margin | 11.1% | 11.2% |
| Revenue YoY | 29.6% | -15.3% |
| Net Profit YoY | 367.5% | 124.3% |
| EPS (diluted) | $1.14 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $249.0M | ||
| Q3 25 | $227.8M | $315.0M | ||
| Q2 25 | $211.4M | $342.0M | ||
| Q1 25 | $197.1M | $282.0M | ||
| Q4 24 | $190.6M | $294.0M | ||
| Q3 24 | $148.3M | $319.0M | ||
| Q2 24 | $138.0M | $360.0M | ||
| Q1 24 | $137.4M | $257.0M |
| Q4 25 | $27.5M | $28.0M | ||
| Q3 25 | $26.6M | $-37.0M | ||
| Q2 25 | $8.5M | $79.0M | ||
| Q1 25 | $15.7M | $-98.0M | ||
| Q4 24 | $-10.3M | $-115.0M | ||
| Q3 24 | $-24.2M | $-40.0M | ||
| Q2 24 | $-2.3M | $62.0M | ||
| Q1 24 | $18.2M | $70.0M |
| Q4 25 | 14.1% | -19.3% | ||
| Q3 25 | 15.9% | 1.6% | ||
| Q2 25 | 6.6% | 26.3% | ||
| Q1 25 | 13.3% | -82.6% | ||
| Q4 24 | -2.3% | -188.1% | ||
| Q3 24 | -13.8% | 15.4% | ||
| Q2 24 | 3.7% | 18.3% | ||
| Q1 24 | 14.8% | -8.2% |
| Q4 25 | 11.1% | 11.2% | ||
| Q3 25 | 11.7% | -11.7% | ||
| Q2 25 | 4.0% | 23.1% | ||
| Q1 25 | 8.0% | -34.8% | ||
| Q4 24 | -5.4% | -39.1% | ||
| Q3 24 | -16.3% | -12.5% | ||
| Q2 24 | -1.7% | 17.2% | ||
| Q1 24 | 13.2% | 27.2% |
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | $-0.40 | ||
| Q2 25 | $0.36 | $0.84 | ||
| Q1 25 | $0.69 | $-1.05 | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | $-0.43 | ||
| Q2 24 | $-0.14 | $0.66 | ||
| Q1 24 | $0.82 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $960.0M |
| Total DebtLower is stronger | — | $6.2B |
| Stockholders' EquityBook value | $540.7M | $10.9B |
| Total Assets | $1.4B | $19.6B |
| Debt / EquityLower = less leverage | — | 0.57× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $960.0M | ||
| Q3 25 | $262.6M | $711.0M | ||
| Q2 25 | $217.8M | $880.0M | ||
| Q1 25 | $149.8M | $1.5B | ||
| Q4 24 | $144.9M | $283.0M | ||
| Q3 24 | $145.0M | $290.0M | ||
| Q2 24 | $240.1M | $281.0M | ||
| Q1 24 | $228.6M | $245.0M |
| Q4 25 | — | $6.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $5.3B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $540.7M | $10.9B | ||
| Q3 25 | $505.8M | $11.0B | ||
| Q2 25 | $436.8M | $11.3B | ||
| Q1 25 | $418.6M | $12.6B | ||
| Q4 24 | $403.7M | $12.9B | ||
| Q3 24 | $405.9M | $13.6B | ||
| Q2 24 | $455.8M | $13.9B | ||
| Q1 24 | $452.0M | $14.0B |
| Q4 25 | $1.4B | $19.6B | ||
| Q3 25 | $1.4B | $19.1B | ||
| Q2 25 | $1.3B | $20.5B | ||
| Q1 25 | $1.3B | $21.4B | ||
| Q4 24 | $1.3B | $20.3B | ||
| Q3 24 | $1.3B | $20.9B | ||
| Q2 24 | $920.8M | $21.7B | ||
| Q1 24 | $914.5M | $22.3B |
| Q4 25 | — | 0.57× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.41× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $186.0M |
| Free Cash FlowOCF − Capex | $29.1M | $-88.0M |
| FCF MarginFCF / Revenue | 11.8% | -35.3% |
| Capex IntensityCapex / Revenue | 0.5% | 110.0% |
| Cash ConversionOCF / Net Profit | 1.10× | 6.64× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $-219.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $186.0M | ||
| Q3 25 | $44.1M | $231.0M | ||
| Q2 25 | $75.8M | $232.0M | ||
| Q1 25 | $35.0M | $90.0M | ||
| Q4 24 | $15.9M | $283.0M | ||
| Q3 24 | $12.5M | $208.0M | ||
| Q2 24 | $17.4M | $231.0M | ||
| Q1 24 | $18.3M | $78.0M |
| Q4 25 | $29.1M | $-88.0M | ||
| Q3 25 | $38.0M | $-283.0M | ||
| Q2 25 | $71.8M | $151.0M | ||
| Q1 25 | $32.5M | $1.0M | ||
| Q4 24 | $13.5M | $231.0M | ||
| Q3 24 | $7.7M | $152.0M | ||
| Q2 24 | $13.0M | $162.0M | ||
| Q1 24 | $13.7M | $14.0M |
| Q4 25 | 11.8% | -35.3% | ||
| Q3 25 | 16.7% | -89.8% | ||
| Q2 25 | 34.0% | 44.2% | ||
| Q1 25 | 16.5% | 0.4% | ||
| Q4 24 | 7.1% | 78.6% | ||
| Q3 24 | 5.2% | 47.6% | ||
| Q2 24 | 9.4% | 45.0% | ||
| Q1 24 | 10.0% | 5.4% |
| Q4 25 | 0.5% | 110.0% | ||
| Q3 25 | 2.7% | 163.2% | ||
| Q2 25 | 1.9% | 23.7% | ||
| Q1 25 | 1.3% | 31.6% | ||
| Q4 24 | 1.3% | 17.7% | ||
| Q3 24 | 3.2% | 17.6% | ||
| Q2 24 | 3.2% | 19.2% | ||
| Q1 24 | 3.3% | 24.9% |
| Q4 25 | 1.10× | 6.64× | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | 2.94× | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 3.73× | ||
| Q1 24 | 1.00× | 1.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
XIFR
| Renewable Energy Sales | $238.0M | 96% |
| Related Party | $8.0M | 3% |
